Company / Free Cash Flow
Adaptive Biotechnologies Corp Free Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$48.9M
FY2025
5-year range
-$254.5M / -$48.9M
FY2021-FY2025
Trend
+50.5%
vs FY2024
Sector context
#81 of 194
Health Care
What the data says
At -$49M, Adaptive Biotechnologies Corp's free cash flow ranks #81 of 194 in the Health Care sector. Free Cash Flow has increased for 4 consecutive years, from -$254M in FY2021 to -$49M in FY2025.
Based on SEC 10-K filings.
-$49M in FY2025.
Improved from -$167M to -$49M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#81 of 194 in Health CareTop 42% of 194This company -$48.9M Sector average $470.8M
▼
-110.4% below sector average
Key checks
Key Insights
- Adaptive Biotechnologies Corp's free cash flow has grown for 4 consecutive years.
- In FY2025, free cash flow increased 50.5% year-over-year.
- Ranks #81 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -1.45 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$48.9M | +50.5% |
| FY2024 | -$98.9M | +40.8% |
| FY2023 | -$167.0M | +16.6% |
| FY2022 | -$200.3M | +21.3% |
| FY2021 | -$254.5M | -51.0% |
| FY2020 | -$168.5M | -186.8% |
| FY2019 | $194.2M | +603.7% |
| FY2018 | -$38.6M | -3.4% |
| FY2017 | -$37.3M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026